NASDAQ:CLYM Climb Bio (CLYM) Stock Price, News & Analysis $2.38 +0.19 (+8.68%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Climb Bio Stock (NASDAQ:CLYM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Climb Bio alerts:Sign Up Key Stats Today's Range$2.17▼$2.4250-Day Range$1.18▼$2.3852-Week Range$1.05▼$8.79Volume799,762 shsAverage Volume778,093 shsMarket Capitalization$161.28 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass. Read More Climb Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreCLYM MarketRank™: Climb Bio scored higher than 69% of companies evaluated by MarketBeat, and ranked 293rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingClimb Bio has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClimb Bio has only been the subject of 3 research reports in the past 90 days.Read more about Climb Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Climb Bio are expected to grow in the coming year, from ($1.57) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Climb Bio is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Climb Bio is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClimb Bio has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Climb Bio's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CLYM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClimb Bio does not currently pay a dividend.Dividend GrowthClimb Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CLYM. News and Social Media3.2 / 5News Sentiment0.73 News SentimentClimb Bio has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Climb Bio this week, compared to 1 article on an average week.Search Interest7 people have searched for CLYM on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows4 people have added Climb Bio to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,540.00 in company stock.Percentage Held by InsidersOnly 0.80% of the stock of Climb Bio is held by insiders.Percentage Held by Institutions69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Climb Bio's insider trading history. Receive CLYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address CLYM Stock News HeadlinesClimb Bio (NASDAQ:CLYM) Coverage Initiated at Robert W. BairdAugust 18, 2025 | americanbankingnews.comAnalysts Set Climb Bio, Inc. (NASDAQ:CLYM) Target Price at $9.00August 18, 2025 | americanbankingnews.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year. | Weiss Ratings (Ad)Climb Bio, Inc. (NASDAQ:CLYM) surges 12%; private equity firms who own 54% shares profited along with institutionsAugust 17, 2025 | finance.yahoo.comClimb Bio (NASDAQ:CLYM) Raised to Strong-Buy at Baird R WAugust 17, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for Climb Bio Q3 Earnings?August 17, 2025 | americanbankingnews.comBaird Initiates Coverage of Climb Bio (CLYM) with Outperform RecommendationAugust 16, 2025 | msn.comClimb Bio initiated with an Outperform at Baird on budoprutug potentialAugust 15, 2025 | msn.comSee More Headlines CLYM Stock Analysis - Frequently Asked Questions How have CLYM shares performed this year? Climb Bio's stock was trading at $1.80 on January 1st, 2025. Since then, CLYM shares have increased by 32.2% and is now trading at $2.38. How were Climb Bio's earnings last quarter? Climb Bio, Inc. (NASDAQ:CLYM) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.06. Who are Climb Bio's major shareholders? Climb Bio's top institutional shareholders include Diadema Partners LP (1.04%), Nan Fung Trinity HK Ltd. (0.69%), Shay Capital LLC (0.61%) and Geode Capital Management LLC (0.46%). View institutional ownership trends. How do I buy shares of Climb Bio? Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/12/2025Today8/23/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLYM Previous SymbolNASDAQ:CLYM CIK1768446 Webclimbbio.com Phone866-857-2596FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Price Target for Climb Bio$9.00 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside+278.2%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.90 million Net MarginsN/A Pretax MarginN/A Return on Equity-23.10% Return on Assets-22.47% Debt Debt-to-Equity RatioN/A Current Ratio14.08 Quick Ratio14.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / Book0.87Miscellaneous Outstanding Shares67,764,000Free Float67,222,000Market Cap$161.28 million OptionableN/A Beta-0.11 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:CLYM) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.